Guanfacine

Guanfacine is the odd one out on this list; a non-stimulant that treats ADHD from a completely different direction. It is a selective alpha-2A adrenergic agonist, and its whole trick plays out in the prefrontal cortex: by stimulating postsynaptic alpha-2A receptors on the dendritic spines of PFC neurons, it closes HCN channels and effectively strengthens the network connections that keep attention and working memory online. The result is better signal-to-noise up top, so impulsivity and distractibility ease off without the dopamine-releasing shove of a classic stimulant.

It actually started life as a blood pressure medication (Tenex) before the extended-release version (Intuniv) became an ADHD staple, and that history explains its main quirks: it can lower blood pressure and heart rate and it tends to be sedating, especially early on, so timing and gentle titration matter and you should not stop it abruptly. It is prescription-only but not a controlled substance, and it pairs remarkably well with stimulants, taking the edge off while adding its own calm, steady focus.

Strong evidence for ADHD (ages 6 to 17), mono or adjunct to stimulants

Generally well tolerated but not benign, and it has a narrow therapeutic window. The most common effects are somnolence, sedation, fatigue and lethargy, usually worst in the first one to three weeks and often easing by two to three weeks; evening dosing lets the sedation overlap with sleep. Dizziness, headache, dry mouth (very common), constipation, upper abdominal pain and nausea also occur.

Cardiovascular: because it lowers heart rate and blood pressure it can cause orthostatic hypotension (lightheadedness on standing, so change position slowly), bradycardia and, rarely, fainting; blood pressure, heart rate and rhythm should be monitored, and combining it with other blood-pressure-lowering agents needs caution. Some people notice cold, color-changing fingers (Raynaud's phenomenon).

Other subjective effects: a distinctive sense that breathing has become "manual", a feeling of not getting a satisfying deep breath with an urge to yawn, which can itself provoke anxiety; food may taste flatter, colors look less vivid and pain feel duller. Sexual side effects include reduced libido, erectile difficulty and delayed orgasm, though a minority report the opposite from lower performance anxiety.

At doses above a person's own optimum, guanfacine can cause emotional blunting, the so-called "zombie effect": anhedonia, apathy, loss of motivation and sometimes paradoxical anxiety, irritability or low mood. This is dose-dependent and usually reverses when the dose is lowered, which is why the lowest effective dose is strongly preferred. Sleep effects are mixed: it can quiet racing thoughts at bedtime yet cause middle-of-the-night waking (often around 2 to 4 am) and vivid dreams, with nightmares or night terrors in some children, which shifting the dosing time can ease.

Over the long term, tolerance (tachyphylaxis) can develop: an initial several-month "honeymoon" of strong benefit may fade over one to two years as alpha-2A receptors downregulate, prompting dose increases; a supervised drug holiday or a cross-taper to clonidine can help reset it. It must never be discontinued abruptly, because chronic use quiets sympathetic output and the body compensates; stopping suddenly can cause rebound hypertension, a racing heart, anxiety, flushing, sweating, disrupted sleep and a return of ADHD symptoms, so the dose is tapered by no more than 1 mg every three to seven days.

Interactions: metabolized by CYP3A4, so strong inhibitors such as ketoconazole can roughly triple extended-release exposure (more sedation and hypotension), while inducers such as rifampin or carbamazepine can cut exposure by around 70% and blunt the effect; it can raise valproate levels. Alcohol adds strongly to its sedation and can sharply lower alcohol tolerance, so combining them is discouraged. Doses are reduced in significant kidney impairment. Genetics may matter too: in one analysis, carriers of certain P-glycoprotein (ABCB1) variants showed markedly greater ADHD improvement, consistent with guanfacine being a transporter substrate. It has no abuse potential.

Guanfacine is a CYP3A4 substrate, and its US label warns that strong CYP3A4 inhibitors such as ketoconazole raise guanfacine exposure and call for dose reduction, while strong inducers such as rifampin lower exposure and may require a dose increase. As a central alpha-2A agonist it produces additive hypotension, bradycardia, sedation, and syncope risk when combined with other antihypertensives, CNS depressants, or alcohol. The label also notes that guanfacine can increase plasma concentrations of valproic acid, and abrupt discontinuation alongside other sympatholytics can provoke rebound hypertension. These interactions derive from the FDA-approved prescribing information and supporting pharmacokinetic studies. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Guanfacine is a selective alpha-2A adrenergic receptor agonist first developed by the Wander/Sandoz group and introduced in the 1970s as an antihypertensive, marketed in Europe under names such as Estulic and in the US as Tenex. Its blood-pressure-lowering action reflects central sympathetic dampening rather than stimulant activity. Decades later an extended-release formulation was developed by Shire and, on September 2, 2009, the FDA approved it as Intuniv for ADHD in children and adolescents aged 6 to 17, making it the first selective alpha-2A agonist cleared for that indication. Unlike the stimulants it is a non-scheduled medicine, which shaped its adoption as a non-stimulant ADHD option.